ABT
Abbott LaboratoriesEvidence as of 2026-09-11The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on ABT
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndro…
Management team
- Ms. Lisa D. Earnhardt · Executive VP & Group President of Medical DevicesFind on LinkedIn
- Mr. Daniel Gesua Sive Salvadori · Executive VP and Group President of Established Pharmaceuticals & Nutritional ProductsFind on LinkedIn
- Mr. Hubert L. Allen J.D. · Executive VP, General Counsel & SecretaryFind on LinkedIn
- Mr. Philip P. Boudreau · CFO & Executive VP of FinanceFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.5 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Cautious ( -0.5 ) with high confidence. Revenue for the fiscal quarter ended 2026-03-31 was $ 11,164,000,000, up from $ 10,358,000,000 in the fiscal quarter ended 2025-03-31, while operating income compressed to $ 1,345,000,000 in the fiscal quarter ended 2026-03-31 versus $ 2,052,000,000 in the fiscal quarter ended 2025-06-30 and $ 2,057,000,000 in the fiscal quarter ended 2025-09-30. Net income and diluted EPS for the fiscal quarter ended 2026-03-31 were $ 1,077,000,000 and $ 0.61, respectively, each below the interim peaks reported in the fiscal quarters ended 2025-06-30 and 2025-09-30.
Liquidity and balance-sheet items show tension: cash and cash equivalents fell to $ 6,803,000,000 as of 2026-03-31 while long‑term noncurrent debt rose to $ 29,638,000,000 as of 2026-03-31 (from $ 9,896,000,000 as of 2025-12-31). Filings show Abbott completed the Exact Sciences acquisition on 2026-03-23 and included about $ 1.0 billion of sales from Exact Sciences in the Diagnostic Products segment; the company disclosed plans to fund that deal with roughly $ 20,000,000,000 of borrowings and later reported settlements totaling about $ 670,000,000 for additional NEC claims, leaving roughly 1,700 lawsuits pending covering about 12,700 infants.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was $11,164,000,000 in fiscal Q1 2026, ended 31 March 2026, up from $10,358,000,000 in fiscal Q1 2025, ended 31 March 2025.
XBRL companyfacts · 0001628280-26-028357Operating income was $1,345,000,000 in fiscal Q1 2026, ended 31 March 2026, down from $2,052,000,000 in fiscal Q2 2025, ended 30 June 2025 and $2,057,000,000 in fiscal Q3 2025, ended 30 September 2025.
XBRL companyfacts · 0001628280-26-028357Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
In a Form 8-K filed August 20, 2026, Abbott stated it entered into agreements to resolve the Gill lawsuit and necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million.
8-K filed 2026-08-20The same Form 8-K filed August 20, 2026 reports that after the settlements there remain approximately 1,700 lawsuits pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants.
8-K filed 2026-08-20Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Abbott's short-term momentum is mixed: momentum over 3 months is +16.7% while momentum over 6 months is -5.7% and momentum_12_1 is -17.0%.
Moneyta signal set · 2026-09-10weakened in debatePrice sits slightly below trend: price is -1.6% vs the 50-day SMA and -2.0% vs the 200-day SMA (fiscal context as of the data date).
Moneyta signal set · 2026-09-10Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
13F filers reported aggregate ABT holdings valued at $138.15B as of 2026-03-31.
13F holdings · 3071 filers · as of 2026-03-31Reported 13F aggregate value fell by 18.2% quarter-over-quarter and the filer count declined by 203 (holder_count_delta_qoq = -203) as of the 13F period ended 2026-03-31.
13F holdings · 3071 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets ran a report noting FDA approval of Abbott's TactiFlex Duo, describing the approval as expanding Abbott's AFib ablation portfolio with dual PFA and RF energy options and supporting broader U.S. adoption.
News · finance.yahoo.com · 2026-09-09At least two investment-research roundup pieces named Abbott among the top research reports of the day, indicating company-specific analyst attention in broader research coverage.
News · finance.yahoo.com · 2026-09-10Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Robert B. Ford (CHAIRMAN AND CEO) reported a sale of 218,535 shares valued at "$25.3M" on 2026-08-25.
Form 4 · Ford Robert B (CHAIRMAN AND CEO) · $6.7M code M · 2026-08-25Robert B. Ford (CHAIRMAN AND CEO) reported a sale of 180,297 shares valued at "$20.9M" on 2026-08-25.
Form 4 · Ford Robert B (CHAIRMAN AND CEO) · $6.7M code M · 2026-08-25Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model reports an implied free cash flow (FCF) growth rate of 36.1% (0.361) that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month (TTM) free cash flow is $3,239,000,000 and FCF per share is $1.854.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-level items point to a constructive read: top-line revenue and net-sales growth are clear across consecutive reported periods (fundamentals-0, filings-2), with the March 2026 Exact Sciences purchase explicitly contributing roughly $1.0 billion of diagnostic sales (filings-3). Product-approval news for TactiFlex Duo (news-0) and a materially positive dividend profile (market-4) align with institutional support and ETF inclusion (ownership-0, ownership-2, ownership-3), suggesting continued investor interest. Where the bear case highlights higher leverage, lower operating income and EPS, and insider sales, those items coincide temporally with the acquisition and one-time charges; the acquisition-related debt and cash movements (filings-3, fundamentals-6, fundamentals-7) explain much of the balance-sheet shifts while still showing expanding revenue. Valuation-model stress tests that imply very high FCF growth (valuation-0, valuation-2, valuation-5) flag modeling tension, but observed TTM FCF (valuation-1) provides a concrete baseline to evaluate those assumptions rather than relying solely on the implied growth figure.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.35
43 surviving claims rest on 18 distinct sources; the heaviest analyst carries 19% of them, and 98% of what the desk raised survived the debate.
The read rests on a moderately broad evidence base but a relatively small set of dominant contributors, so individual sources and a few heavy analysts can sway the overall picture. High survival through debate suggests internal robustness of the desk's vetting, but dependence on a limited number of material filings and the largest analyst means the conclusions carry some source-concentration fragility.
Peer context · computed, not argued
12-1 momentum ranks 4th of 5 in Medical Devices (as of 2026-09-10).
6-month relative strength ranks 3rd of 5 in Medical Devices (as of 2026-09-10).
90-day volatility ranks 4th of 5 in Medical Devices (as of 2026-09-10).
dividend yield ranks 1st of 5 in Medical Devices (as of 2026-09-10).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
11 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer−0.8 to the score
11 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.2 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.4 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
15 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot−0.7 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on ABT Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.